ERBB2 and gastric cancer: This ToGA study determined that 22.1% (810/3665) of gastric cancer cases overexpressed HER2, and trastuzumab, a monoclonal antibody that targets HER2, could be considered a new standard option for patients with HER2-positive gastric carcinomas and be helpful for improving survival in these patients [23].